Adverse events after pneumococcal vaccination

Area of Science:

• Immunology and Vaccinology
• Public Health
• Clinical Research

Background:

• Pneumococcal infections pose a significant health risk, particularly to vulnerable populations.
• The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is indicated for individuals at increased risk of pneumococcal disease.

Purpose of the Study:

• To investigate the incidence and nature of adverse events following the administration of the 23-valent pneumococcal polysaccharide vaccine.
• To assess the safety profile of PPSV23 in individuals for whom vaccination is recommended.

Main Methods:

• A prospective study involving 152 individuals receiving intramuscular PPSV23 vaccination.
• Adverse events were monitored for symptoms appearing within 48 hours post-vaccination.
• Statistical analysis, including chi-square and logistic regression, examined the correlation of age, gender, and clinical profile with adverse events.

Main Results:

• The mean age of participants was 61.8 years, with 99% receiving their first dose.
• Local injection site reactions, predominantly mild pain (97.2%), occurred in 23.7% of subjects.
• General symptoms like malaise or fever were reported by 12.8%, with no significant correlation to demographic or clinical factors.

Conclusions:

• The 23-valent pneumococcal polysaccharide vaccine demonstrates a favorable safety profile with minimal adverse reactions upon first-time administration.
• Despite its safety, the vaccine's recommendation and uptake remain low in the studied region, even among high-risk groups.